Active Ingredient(s): Upadacitinib
FDA Approved: * August 16, 2019
Pharm Company: * ABBVIE INC
Category: Arthritis

Upadacitinib, sold under the brand name Rinvoq, is a Janus kinase (JAK) inhibitor medication for the treatment of moderately to severely active rheumatoid arthritis and psoriatic arthritis in adults where methotrexate (a drug used to treat active arthritis) did not work well or could not be tolerated.[8] It was approved for medical use in the United States and in the European Union in 2019,[8][9][5] and was developed by the biote... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
1 Discussion

Dosage List

Rinvoq 45 mg Oral Tablet, Extended Release
NDC: 0074-1043
Abbvie Inc.
Rinvoq 15 mg Oral Tablet, Extended Release
NDC: 0074-2306
Abbvie Inc.
Rinvoq 30 mg Oral Tablet, Extended Release
NDC: 0074-2310
Abbvie Inc.

Popular Topics

Rinvoq for rheumatoid arthritis

Hi ~ Just got the rheumatoid arthritis tap on the shoulder today. Rinvoq seems to be advertised a lot but I’d sure...